JUBLINGREA Jubilant Ingrevia Q3 FY25 results (Oct–Dec 2024) and concall
Jubilant Ingrevia outlined its ambitious 'Pinnacle 345' strategy, aiming for substantial revenue and EBITDA growth by FY30, driven by a strategic shift towards high-margin Specialty and Nutrition segments. The company reported improved ROCE and significant progress in CDMO contracts and sustainability initiatives. While the Chemical Intermediates business faced headwinds, management expressed confidence in its transformation journey, supported by new leadership, R&D investments, and a strong focus on customer-centricity and operational excellence.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 1,057 |
| EBITDA | 138 |
| Net profit | 69 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
